Radioprotector Compounds for Selective Tissue Protection
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current radioprotector agents are either too toxic or insufficiently active for clinical use and require pre-exposure administration, limiting their application in protecting normal tissues from radiation damage.
Innovation Solution
Development of radioprotector compounds, including 3,3′-diindolylmethane (DIM) and related structures, which can be administered before or after radiation exposure to protect non-tumor cells and kill tumor cells, thereby treating cancer while minimizing harm to normal tissues.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If current commercially available radioprotector agents are used, then radiation protection is provided, but the agents are too toxic or insufficiently active to be clinically useful
Solution Approach 1:
The patent modifies the chemical structure of radioprotector agents by changing molecular parameters (adding specific functional groups, modifying core structures) to achieve optimal balance between protective effectiveness and toxicity reduction. The compounds feature specific structural elements like indole cores, hydroxyl groups, and carbonyl groups that contribute to both protection and reduced toxicity
Solution Approach 2:
The patent develops composite molecular structures combining multiple functional groups (indole, hydroxyl, carbonyl, amino groups) within single radioprotector molecules. This composite approach allows different parts of the molecule to contribute to different functions: radiation scavenging, free radical neutralization, and reduced toxic interaction with biological systems
2Reliability
If current radioprotector agents are administered, then protection from radiation damage is achieved, but administration must occur prior to radiation exposure which limits use to intentional or expected exposures
Solution Approach 1:
The patent describes compounds that can be administered before radiation exposure to establish protective mechanisms in advance, including scavenging free radicals and protecting cellular structures. The molecular structure enables rapid activation upon exposure, providing immediate protection
Solution Approach 2:
The patent develops compounds that can be administered after radiation exposure to mitigate damage. The molecules scavenge harmful free radicals generated by radiation and convert them into harmless substances, effectively treating the harm after it occurs. This retroactive protection capability provides timing flexibility
3Object-affected harmful factors
If radioprotector agents are used to protect normal tissues, then radiation damage to normal cells is reduced, but the ability to selectively protect non-tumor cells while killing tumor cells is limited
Solution Approach 1:
The patent describes compounds with specific molecular properties that create different effects in different cell types. The molecular structure interacts differently with tumor cells versus normal cells, providing selective protection. The compounds may have affinity for specific cellular components that are more abundant or accessible in normal cells
Solution Approach 2:
The patent describes compounds that can differentiate between protected and unprotected cells, potentially by exploiting differences in cellular metabolism, membrane permeability, or intracellular environment between tumor and normal cells. This inversion of the typical radioprotector approach enables selective action
Data Source
AI summary
Radioprotector compounds including 3,3′-diindolylmethane (DIM) analogs, are provided. Further provided are methods for their use in reducing or preventing radiation damage, killing a tumor cell and protecting a non-tumor cell, and treating cancer.